Apertura Opens Its AAV Capsid Playbook to Wider Access

Gene therapy developer Apertura Gene Therapy has manufactured its engineered AAV capsid, TfR1 CapX, in clinical batches of up to 500 liters, using standard unit operations and commercially available reagents — and it is now offering that manufacturing know-how to academic and for-profit partners through material transfer agreements and hands-on advisory support.

Jorge Santiago-Ortiz, PhD, vice president of CMC and regulatory affairs at Apertura, laid out the company's approach at the Bioprocessing Summit in Boston. He described the development and manufacturing history of the lead capsid as "reassuringly uneventful," a phrase that carries weight in a field where engineered capsids often create novel analytical and process burdens.

"Giving access to capsids is in everyone's best interests to advance the field," Santiago-Ortiz said. "And we have already formed a number of partnerships with different types of institutions, for example, foundations, academic institutions, and for-profit organizations too."

For context, 500 liters represents a mid-scale clinical manufacturing volume for AAV production — large enough to demonstrate that an engineered capsid does not require bespoke processes that inflate cost of goods.

What does the capsid claim rest on?

Apertura positions TfR1 CapX as a best-in-class novel AAV capsid for delivery to the central nervous system, achieving efficient transduction even at low doses. That claim comes from the company itself, and the summit talk did not include independent validation data, peer-reviewed potency comparisons, or dose-ranging clinical results.

The company points to its internal discipline as the foundation of its manufacturability record. Santiago-Ortiz said Apertura considered manufacturability from the earliest design stages, alongside the modifications that any group would need to make to standard analytical techniques when characterizing a bespoke capsid. In practice, that means partners adopting TfR1 CapX should budget for adapted analytics rather than off-the-shelf assays.

Production has occurred both internally and at contract manufacturers and other partner facilities, which suggests the process has transferred to at least one external site — though the company did not specify how many transfers succeeded, at what yields, or over what timeline.

How open is the access model?

According to Santiago-Ortiz, the element of his talk that resonated most with the Bioprocessing Summit audience was the access strategy itself. The mechanism centers on Material Transfer Agreements, or MTAs, which allow academic researchers and even for-profit companies to evaluate the capsid before committing to deeper partnerships.

The offering extends beyond the capsid and its associated plasmid. Apertura also advises partners on:

• Manufacturing strategy and scale-up
• Nonclinical development
• Regulatory strategy
• Analytical development for bespoke capsids

"As soon as a partnership is announced, we're as proactive as possible in providing advice and guidance," Santiago-Ortiz said. "We want to be open and reachable and answer the questions partners might have."

The company also acts as a connector, introducing partners who need contract manufacturing capacity to organizations with relevant process experience. "We connect different parties who have developed different experience and, hopefully, this list of partners will grow as more people adopt this technology and establish their capability to manufacture this virus," he added.

What remains unsaid

Several questions sit outside the published record. The financial terms of the MTAs were not disclosed, nor were the identities of the contract manufacturers or the number of partnerships signed to date. No clinical-stage efficacy data for TfR1 CapX accompanied the manufacturing discussion, so program risk remains unquantified from public information.

For R&D managers weighing capsid platforms, the model reduces one barrier — process uncertainty — while leaving licensing economics and clinical validation as due-diligence items.

Santiago-Ortiz indicated the partner network will expand as more organizations adopt the capsid and build their own manufacturing capability, positioning Apertura's roadmap as a bet that open access, rather than exclusivity, will drive the technology's adoption across the gene therapy field.